Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
US-Israeli Biotech Startup Immunai Raises $20 Million
Error: Contact form not found.
by Reuters and Algemeiner Staff
Scientists at work in laboratory. Photo: Wikimedia Commons.
US-Israeli startup Immunai, which has mapped the immune system to help detect and treat disease, said on Thursday it has raised $20 million in seed funding led by Viola Ventures and TLV Partners.
The funds will be used to further develop its technology while expanding its team of scientists, engineers, and machine learning experts.
“Cell therapies and cancer immunotherapies have revolutionized medicine in the last few years and are expected to continue for the near future,” the company said. “However, due to the incredible complexity of the immune system … it is prohibitively hard to predict how drugs will affect immune cells.”
Immunai said its platform can help drug companies identify more subtle nuances in cell abundances and cell function to more accurately measure the efficacy of immunotherapies.
“This helps increase the speed in which drugs are developed and brought to market,” Chief Technology Officer Luis Voloch said.
Founded in December 2018, the company is headquartered in New York with a research and development center in Israel.
